A Phase 2 interventional study of Placebo and Rilzabrutinib in Atopic Dermatitis, sponsored by Sanofi. Completed at 31 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2021, is one of 8 in phase 2, and was the 14th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:
Sanofi · Sites in Qatar, Saudi Arabia, United Arab Emirates
Ages 12+
Sanofi · Sites in United States, Canada, China and 6 more countries
Ages 12+
Sanofi · Sites in Italy
Ages 6 mo–17 yrs
Sanofi
Ages 12+
Sanofi
Ages 18+
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 112 across the 28 interventional studies, 266 across the 15 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
6 of the studies in Dermatitis, Atopic by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT06837454SanofiFrench Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) | 2027-05-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies in Dermatitis, Atopic by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or inadequate response to topical corticosteroids (TCS).
The total study duration per participant was expected to be approximately 21 weeks, including up to 4 weeks of screening, 16 weeks of on-treatment double-blind period, 1 week of post-treatment follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to rilzabrutinib orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).
Drug: Placebo
Participants received rilzabrutinib 400 milligrams (mg) orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).
Drug: Rilzabrutinib
Participants received placebo matched to rilzabrutinib orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).
Drug: Placebo
Participants received rilzabrutinib 400 mg orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).
Drug: Rilzabrutinib
Pharmaceutical form: Tablet Route of administration: Oral
Pharmaceutical form: Tablet Route of administration: Oral
Also known as: PRN1008/SAR444671
Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in atopic dermatitis (AD). Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of body surface area (BSA) involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.
Time frame: Baseline (Day 1) to Week 16
Percentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 16
IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity.
Time frame: Week 16
Percentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 16
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-75 were defined as participants with reduction of EASI score by ≥75% from baseline.
Time frame: Baseline (Day 1) and at Week 16
Percentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 16
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.
Time frame: Baseline (Day 1) and at Week 16
Number of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.
Time frame: Baseline (Day 1) and Week 16
Absolute Change From Baseline to Week 16 In EASI Score
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.
Time frame: Baseline (Day 1) to Week 16
Percentage of Participants Achieving EASI-50/90 (Reduction of EASI Score by ≥50% or ≥90% From Baseline) at Week 16
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-50/90 were defined as participants with reduction of EASI score by ≥50% or ≥90% from baseline respectively.
Time frame: Baseline (Day 1) and at Week 16
Change From Baseline to Week 16 in Percent BSA of AD
BSA affected by AD were assessed for each section of the body (the possible highest score for each region was: head and neck \[10%\], trunk including genitalia \[30%\], upper limbs \[20%\], lower limbs \[40%\]) and were reported as a percentage of all major body sections combined. Total score ranges from 0% to 100%. The higher score indicates a worse value and a lower score indicates a better value. Baseline was defined as the Day 1 assessment value.
Time frame: Baseline (Day 1) to Week 16
Absolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.
Time frame: Baseline (Day 1) to Week 16
Percent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.
Time frame: Baseline (Day 1) to Week 16
Percentage of Participants Achieving IGA*BSA-50/75/90 (Reduction of IGA*BSA by ≥50% or 75% or 90% From Baseline) At Week 16
IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity. Participants who achieved IGA\*BSA-50-75-90 were defined as participants with reduction of IGA\*BSA by ≥50% or 75% or 90% from baseline.
Time frame: Baseline (Day 1) and at Week 16
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and Study Intervention Discontinuation
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent period. SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required.
Time frame: Baseline (Day 1) to 16 weeks
The study was conducted at 31 centers in 7 countries. 61 participants in twice a day (BID) cohort and 106 participants in three times a day (TID) cohort were screened from 09 September 2021 to 24 February 2023, of which 16 in BID cohort and 27 in TID cohort were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.
| Milestone | BID Cohort: Placebo | BID Cohort: Rilzabrutinib 400 mg BID | TID Cohort: Placebo | TID Cohort: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Started | 18 | 27 | 31 | 48 |
| Completed | 14 | 23 | 26 | 31 |
| Not completed | 4 | 4 | 5 | 17 |
| Withdrew: Adverse event (ae): not related to coronavirus disease-2019 (covid-19) | 1 | 1 | 2 | 7 |
| Withdrew: Withdrawal by subject | 3 | 3 | 3 | 10 |
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in atopic dermatitis (AD). Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of body surface area (BSA) involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.
| Percent change | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score | -47.33 ± 9.77 | -53.57 ± 8.25 | -43.33 ± 6.99 | -47.21 ± 6.26 |
IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity.
| Percentage of participants | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 16 | 22.2 | 7.4 | 12.9 | 14.6 |
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-75 were defined as participants with reduction of EASI score by ≥75% from baseline.
| Percentage of participants | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Percentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 16 | 27.8 | 29.6 | 29.0 | 18.8 |
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.
| Percentage of participants | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Percentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 16 | 11.1 | 18.5 | 12.9 | 20.8 |
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.
| Participants | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Number of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period | 2 | 7 | 4 | 13 |
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline was defined as the Day 1 assessment value.
| Scores on a scale | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Absolute Change From Baseline to Week 16 In EASI Score | -12.83 ± 2.31 | -14.00 ± 1.94 | -10.37 ± 2.48 | -11.34 ± 2.20 |
The EASI index is a validated investigator-administered scoring system used to measure the severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100% of BSA involvement with AD. Total score ranged from 0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-50/90 were defined as participants with reduction of EASI score by ≥50% or ≥90% from baseline respectively.
| Percentage of participants | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| EASI-50 | 55.6 | 44.4 | 38.7 | 29.2 |
| EASI-90 | 16.7 | 11.1 | 12.9 | 8.3 |
BSA affected by AD were assessed for each section of the body (the possible highest score for each region was: head and neck \[10%\], trunk including genitalia \[30%\], upper limbs \[20%\], lower limbs \[40%\]) and were reported as a percentage of all major body sections combined. Total score ranges from 0% to 100%. The higher score indicates a worse value and a lower score indicates a better value. Baseline was defined as the Day 1 assessment value.
| Percent of body surface area | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Change From Baseline to Week 16 in Percent BSA of AD | -10.45 ± 4.37 | -15.30 ± 3.61 | -7.35 ± 3.38 | -11.80 ± 3.08 |
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.
| Scores on a scale | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Absolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS | -1.60 ± 0.66 | -3.11 ± 0.52 | -0.83 ± 0.51 | -2.07 ± 0.43 |
The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value.
| Percent change | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| Percent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS | -21.55 ± 8.37 | -43.53 ± 6.80 | -10.36 ± 7.19 | -30.13 ± 6.08 |
IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity. Participants who achieved IGA\*BSA-50-75-90 were defined as participants with reduction of IGA\*BSA by ≥50% or 75% or 90% from baseline.
| Percentage of participants | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| IGA*BSA-50 | 38.9 | 40.7 | 38.7 | 29.2 |
| IGA*BSA-75 | 22.2 | 25.9 | 22.6 | 18.8 |
| IGA*BSA-90 | 5.6 | 18.5 | 9.7 | 10.4 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent period. SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required.
| Participants | BID Cohort: Placebo | BID Cohort: Rilzabrutinib | TID Cohort: Placebo | TID Cohort: Rilzabrutinib |
|---|---|---|---|---|
| TEAEs | 10 | 15 | 19 | 38 |
| TESAEs | 0 | 0 | 1 | 1 |
| AESI | 3 | 0 | 2 | 0 |
| TEAEs leading to studyintervention discontinuation | 0 | 2 | 2 | 9 |
Collected over TEAEs were collected from Baseline (Day 1) to 16 weeks. All-cause mortality (Deaths) was collected throughout the study, approximately 97 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BID Cohort: Placebo | 0/18 (0%) | 0/18 (0%) | 10/18 (55.6%) |
| BID Cohort: Rilzabrutinib 400 mg BID | 0/27 (0%) | 0/27 (0%) | 15/27 (55.6%) |
| TID Cohort: Placebo | 0/31 (0%) | 1/31 (3.2%) | 19/31 (61.3%) |
| TID Cohort: Rilzabrutinib 400 mg TID | 0/48 (0%) | 1/48 (2.1%) | 38/48 (79.2%) |
| Event | BID Cohort: Placebo | BID Cohort: Rilzabrutinib 400 mg BID | TID Cohort: Placebo | TID Cohort: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Abscess LimbInfections and infestations | 0/18 | 0/27 | 1/31 | 0/48 |
| Cutaneous T-Cell LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/18 | 0/27 | 0/31 | 1/48 |
| Event | BID Cohort: Placebo | BID Cohort: Rilzabrutinib 400 mg BID | TID Cohort: Placebo | TID Cohort: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/18 | 8/27 | 1/31 | 15/48 |
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 3/18 | 4/27 | 9/31 | 15/48 |
| DiarrhoeaGastrointestinal disorders | 0/18 | 4/27 | 0/31 | 10/48 |
| Covid-19Infections and infestations | 2/18 | 0/27 | 2/31 | 0/48 |
| AcneSkin and subcutaneous tissue disorders | 1/18 | 0/27 | 3/31 | 0/48 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/18 | 0/27 | 0/31 | 4/48 |
| NasopharyngitisInfections and infestations | 0/18 | 2/27 | 2/31 | 3/48 |
| HeadacheNervous system disorders | 1/18 | 2/27 | 1/31 | 0/48 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/18 | 2/27 | 0/31 | 0/48 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 0/18 | 1/27 | 2/31 | 1/48 |
Randomized population included all participants from screened population who had been allocated to a randomized intervention by interactive response technology (IRT) regardless of whether the intervention was received.
| Age, Continuous(Years) | BID Cohort: Placebo | BID Cohort: Rilzabrutinib 400 mg BID | TID Cohort: Placebo | TID Cohort: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| Mean | 33.9 ± 13.0 | 38.3 ± 16.1 | 33.1 ± 12.4 | 36.1 ± 14.1 | 35.5 ± 14.0 |
| Sex: Female, Male(Participants) | BID Cohort: Placebo | BID Cohort: Rilzabrutinib 400 mg BID | TID Cohort: Placebo | TID Cohort: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| Female | 10 | 15 | 15 | 31 | 71 |
| Male | 8 | 12 | 16 | 17 | 53 |
| Race (NIH/OMB)(Participants) | BID Cohort: Placebo | BID Cohort: Rilzabrutinib 400 mg BID | TID Cohort: Placebo | TID Cohort: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 | 6 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 2 | 4 | 7 |
| White | 16 | 23 | 25 | 38 | 102 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2021 to primary completion in Jun 2023, 21 months.
Results were first posted in Jul 2026, 3 years after primary completion. A results delay was requested in Jun 2024.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 21 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilzabrutinib